It wasn’t too long ago that President Trump said drug makers are “getting away with murder.” But it sure sounds like he’s about to grant them a presidential pardon.

For months, Trump has kept these companies off balance with remarks that suggest he’s willing to consider ideas they find abhorrent in an effort to rein in drug prices. Now, though, his team is reportedly considering moves that would do little to address the problem — and would instead please the pharmaceutical industry.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • We have lot of wishful thinking. No one on the planet will lower their profits and they will get them by hook or crook. If we think that folks in the developing countries will buy expensive drugs when they cannot afford two square meals we must be from a different planet.

    Drug companies have a new mojo and that is hook the patient for a long time on expensive drug. Curing the patient is secondary. Continuous revenue stream is more important to the US companies. They have and exploiting Orphan Drug act. Everything (very few) that has been approved is expensive and for limited population. Approved drugs are expensive and even the doctors are balking.

    Lets us look at another aspect. US does not have the capability (trained manpower) and capacity (plants) to produce Active Pharma Ingredients. It will take time if that is to happen.

    Lowering drug prices needs out of the box thinking and new model. No one wants to go there. Life will go on and prices will rise. That is life! אַז איז לעבן

  • I must be dumb. How are they supposed to strengthen overseas monopoly rights for drug makers and extend patents for drugs in foreign countries?
    If that would be possible, companies would have already done it a long time ago!
    What is sure:“There is zero evidence that raising drug prices in foreign countries lowers them here,”

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy